系统性红斑狼疮血清中的一种赖氨酸结合蛋白可抑制免疫复合物与正常红细胞CR1（1型补体受体）的结合。
A lysine-binding protein in SLE sera inhibits the binding of immune complexes to normal erythrocyte CR1 (complement receptor type 1).
作者信息
Ng Y C, Peters D K, Cederholm-Williams S A, Walport M J
机构信息
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
出版信息
Clin Exp Immunol. 1987 Jul;69(1):89-97.
The binding of 125I-labelled immune complexes (IC) to normal human erythrocyte CR1 (complement receptor type 1) by sera from patients with SLE was found to be significantly decreased compared to normal sera. In 13/29 patients, there was an inhibitor which decreased the binding of opsonized IC in normal sera to normal erythrocytes. It was found in each of the nine patients who had clinically active disease. The inhibitor was shown to be a globulin that was labile at 56 degrees C and bound to lysine; low concentrations of tranexamic acid and of lysine abolished the effects of the inhibitor which suggests that it possesses lysine-binding sites: these may block the CR1-binding site on IC opsonized with complement. This inhibitor may decrease the efficiency of IC carriage by erythrocyte CR1.
与正常血清相比，发现系统性红斑狼疮患者血清中125I标记的免疫复合物（IC）与正常人红细胞CR1（1型补体受体）的结合显著减少。在29例患者中的13例中，存在一种抑制剂，它可降低正常血清中调理的IC与正常红细胞的结合。在9例临床活动期疾病患者中均发现了这种抑制剂。该抑制剂被证明是一种在56℃不稳定且与赖氨酸结合的球蛋白；低浓度的氨甲环酸和赖氨酸可消除该抑制剂的作用，这表明它具有赖氨酸结合位点：这些位点可能会阻断补体调理的IC上的CR1结合位点。这种抑制剂可能会降低红细胞CR1转运IC的效率。
Zotero 插件